Boss Mark Read (pictured) said that although revenues were hit by weaker client discretionary spending, growth of 2% was seen ...
Hvivo anticipates that full-scale Hmpv human challenge trials (HCTs) could commence in the second half of 2025 ...
LONDON - hVIVO plc, a leading early-stage Contract Research Organisation (CRO) known for its human challenge clinical trials, has acquired two Clinical Research Units (CRUs) from CRS Clinical ...
The UK market has faced challenges recently, with the FTSE 100 index closing lower due to weak trade data from China, highlighting concerns about global economic recovery. In such a climate ...
Clinical trials company Hvivo has completed its first acquisition, buying two research units from German group CRS for €10 million. Hvivo, which specialises in early-stage drug development ...
Pharmaceutical services firm hVivo, formerly Open Orphan, has acquired two clinical trial units in Germany from CRS Clinical Research Services Management GmbH for a cash consideration of €10m.
(Alliance News) - hVIVO PLC on Wednesday released an optimistic pre-annual results trading update, and said it expects "further strong growth" next year. However, the stock was down 7.4% at 18.89 ...
(Alliance News) - hVIVO PLC on Monday said it has signed a contract with Inhalon Biopharma Inc to test its antiviral candidate to treat respiratory syncytial virus. The London-based contract ...
LONDON - hVIVO plc, a leading early-stage Contract Research Organisation (CRO) known for its human challenge clinical trials, has acquired two Clinical Research Units (CRUs) from CRS Clinical Research ...
During the randomised, placebo-controlled, double-blind study, healthy volunteers recruited by hVIVO's FluCamp were administered S-337395 once daily for five days. Results showed an 88.94% ...
VIVO plc (AIM: HVO), a fast-growing early-stage Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that, following the success of its pilot human ...